← All trials
NCT04852367
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2021
- Primary completion
- May 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 21, 2021
- Last posted
- Aug 27, 2021
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- National Institute for Health Research, United KingdomCollaborator
- CelsionCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.